Parenteral Manual

Doxycycline (SPECIAL ACCESS PROGRAM)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
VIBRAMYCIN®
Classification: 
Antibiotic
Original Date: 
August 2005
Revised Date: 
September 2011
Indications: 
  • Treatment of infections due to sensitive organisms when oral therapy is not feasible
  • Serious pelvic inflammatory disease
Reconstitution and Stability: 

VIAL SIZE

STERILE WATER for INJECTION REQUIRED

FINAL CONCENTRATION

100 mg

10 mL

10 mg/mL

  • Solutions diluted in D5W and NS to 0.1-1 mg/mL stable 7 days refrigerated and 96 hours at room temperature. 
  • Protect from light
Compatibility: 

- Solutions Compatible: D5W, NS, ringer's solution, ringer's lactate

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: acyclovir, morphine, KCl, dextrose and amino acids,

- Incompatible: lipids, meropenem, heparin, piperacillin/tazobactam (tazocin)

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Direct

NO

IV Intermittent Infusion YES Large Volume Pump ONLY.  Don't use a minibag smaller than 50 mL
Usual dilution: 0.1 - 1 mg/mL
Infusion time: 1-4 hours
IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric (>8 years):

  • Infection: 2-4 mg/kg/day IV divided Q 12-24 hours
  • Maximum: 200 mg/day

Adolescent/Adult:

  • Infection: 100-200 mg/day IV in 1-2 divided doses
  • Pelvic Inflammatory disease: 100 mg IV Q 12 hours x 14 days administered with cefoxitin
Potential hazards of parenteral administration: 
  • Phlebitis; dilute solutions and infuse slowly
  • Avoid extravasation. If extravasation occurs, click HERE for treatment guidelines.    
  • Nausea, diarrhea, anorexia, pseudomembranous colitis
  • Discoloration of teeth in children (< 8 years), photosensitivity, blood dyscrasias
  • Retardation of skeletal development in infants
Notes: 
  • Not recommended for use in children < 8 years (due to associated retardation in skeletal development)
  • Contraindicated in severe hepatic impairment
  • Photosensitivity reactions may occur; avoid prolonged sun exposure or tanning equipment
  • Monitor renal, hepatic and hematologic function
References: 

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.